title: Amyloid PET Imaging: MCI and AD.
abstract: PET with "β-amyloid-specific" molecular imaging probes is proposed for the measurement of brain β-amyloid protein amyloidosis in the new guidelines for diagnosis of Alzheimer disease (AD) at different levels of disease progression. This article discusses limitations of this proposed use pointing to unresolved issues and inconsistencies between PET scan results and correlation with other biomarkers, and with postmortem histopathological studies. These unresolved issues do not warrant the conclusion that PET imaging with "β-amyloid-specific" molecular imaging probes can be used as a biomarker in AD or in the various stages of disease progression.
authors.affiliation: Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, 10833 Le Conte Avenue, CHS B2-086B, Los Angeles, CA 90095-6948, USA. Electronic address: vkepe@mednet.ucla.edu.
authors.forename: Vladimir
authors.initials: V
authors.lastname: Kepe
keywords: Alzheimer disease; Imaging biomarkers; Mild cognitive impairment; Positron emission tomography; “β-amyloid–specific” probes